Melanoma in older patients: declining gap in survival between younger and older patients with melanoma

References

• Netherlands Cancer Registry (NCR). Dutch cancer figures; [cited 2018 Dec 3]. Available from: https://www.cijfersoverkanker.nl/.
   Google Scholar
• World Health Organization. GLOBOCAN 2018; [cited 2019 May 7]. Available from: http://gco.iarc.fr/today/.
   Google Scholar
• Statistics Netherlands. CBS Statline; [cited 2018 Sep 4]. Available from: https://statline.cbs.nl/Statweb/.
   Google Scholar
• Arndt V, Sturmer T, Stegmaier C, et al. Patient delay and stage of diagnosis among breast cancer patients in Germany – a population based study. Br J Cancer. 2002;86:1034–1040.
   PubMed Web of Science ®Google Scholar
• Dale DC. Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. J Support Oncol. 2003;1:11–17.
   PubMedGoogle Scholar
• Macdonald JB, Dueck AC, Gray RJ, et al. Malignant melanoma in the elderly: different regional disease and poorer prognosis. J Cancer. 2011;2:538–543.
   PubMed Web of Science ®Google Scholar
• Grann AF, Froslev T, Olesen AB, et al. The impact of comorbidity and stage on prognosis of Danish melanoma patients, 1987–2009: a registry-based cohort study. Br J Cancer. 2013;109:265–271.
   PubMed Web of Science ®Google Scholar
• Ciocan D, Barbe C, Aubin F, et al. Distinctive features of melanoma and its management in elderly patients: a population-based study in France. JAMA Dermatol. 2013;149:1150–1157.
   PubMed Web of Science ®Google Scholar
• Rees MJ, Liao H, Spillane J, et al. Localized melanoma in older patients, the impact of increasing age and comorbid medical conditions. Eur J Surg Oncol. 2016;42:1359–1366.
   PubMed Web of Science ®Google Scholar
• Percy C, Van Holten V, Muir C, editors. International classification of diseases for oncology. 2nd ed. Geneva (Switzerland): World Health Organization; 1990.
   Google Scholar
• Fritz A, Percy C, Jack A, et al. International classification of diseases for oncology. 3rd ed. Geneva (Switzerland): World Health Organization; 2000.
   Google Scholar
• Sobin LH, Wittekind C. International union against cancer, TNM classification of malignant tumors. 6th ed. New York, NY: Wiley; 2002.
   Google Scholar
• Sobin LH, Gospodarowicz M, Wittekind C. International union against cancer, TNM classification of malignant tumors. 7th ed. New York, NY: Wiley; 2009.
   Google Scholar
• Janssen-Heijnen ML, Houterman S, Lemmens VE, et al. Prognostic impact of increasing age and co-morbidity in cancer patients: a population-based approach. Crit Rev Oncol Hematol. 2005;55:231–240.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Ederer FH, H. Instructions to IBM 650 programmers in processing survival computations. Methodological note No. 10. Bethesda MD: National Cancer Institute; 1959.
   Google Scholar
• Hoejberg L, Gad D, Gyldenkerne N, et al. Trends in melanoma in the elderly in Denmark, 1980–2012. Acta Oncol. 2016;55:52–58.
   PubMed Web of Science ®Google Scholar
• Olazagasti Lourido JM, Ma JE, Lohse CM, et al. Increasing incidence of melanoma in the elderly: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc. 2016;91:1555–1562.
   PubMed Web of Science ®Google Scholar
• Aitken JF, Youlden DR, Baade PD, et al. Generational shift in melanoma incidence and mortality in Queensland, Australia, 1995–2014. Int J Cancer. 2017;142:1528–1535
   PubMed Web of Science ®Google Scholar
• Haluza D, Simic S, Holtge J, et al. Gender aspects of recreational sun-protective behavior: results of a representative, population-based survey among Austrian residents. Photodermatol Photoimmunol Photomed. 2016;32:11–21.
   PubMed Web of Science ®Google Scholar
• Pinault L, Fioletov V. Sun exposure, sun protection and sunburn among Canadian adults. Health Rep. 2017;28:12–19.
   PubMed Web of Science ®Google Scholar
• van der Leest RJ, Zoutendijk J, Nijsten T, et al. Increasing time trends of thin melanomas in the Netherlands: what are the explanations of recent accelerations?. Eur J Cancer. 2015;51:2833–2841.
   PubMed Web of Science ®Google Scholar
• Kruijff S, Bastiaannet E, Francken AB, et al. Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients. Br J Cancer. 2012;107:570–574.
   PubMed Web of Science ®Google Scholar
• Reyes-Ortiz CA, Goodwin JS, Freeman JL, et al. Socioeconomic status and survival in older patients with melanoma. J Am Geriatr Soc. 2006;54:1758–1764.
   PubMed Web of Science ®Google Scholar
• Lachiewicz AM, Berwick M, Wiggins CL, et al. Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program. Arch Dermatol. 2008;144:515–521.
   PubMed Web of Science ®Google Scholar
• Ozao-Choy J, Nelson DW, Hiles J, et al. The prognostic importance of scalp location in primary head and neck melanoma. J Surg Oncol. 2017;116:337–343.
   PubMed Web of Science ®Google Scholar
• Netherlands Comprehensive Cancer Organisation (IKNL). Kankerzorg in Beeld: de oudere patiënt; 2016.
   Google Scholar
• Fleming NH, Tian J, Vega-Saenz de Miera E, et al. Impact of age on the management of primary melanoma patients. Oncology. 2013;85:173–181.
   PubMed Web of Science ®Google Scholar
• Jochems A, Schouwenburg MG, Leeneman B, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2017;72:156–165.
   PubMed Web of Science ®Google Scholar
• Forschner A, Eichner F, Amaral T, et al. Improvement of overall survival in stage IV melanoma patients during 2011–2014: analysis of real-world data in 441 patients of the German Central Malignant Melanoma Registry (CMMR). J Cancer Res Clin Oncol. 2017;143:533–540.
   PubMed Web of Science ®Google Scholar
• Leeneman B, Franken MG, Jochems A, et al. Improved survival with ipilimumab in patients with advanced melanoma in real-world clinical practice: first results of the Dutch Melanoma Treatment Registry. Value Health. 2015;18:A440.
   Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–2516.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364:2517–2526.
   PubMed Web of Science ®Google Scholar
• Chiarion Sileni V, Pigozzo J, Ascierto PA, et al. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res. 2014;33:30.
   PubMed Web of Science ®Google Scholar
• Dutch Institute for Clinical Auditing (DICA). Jaarrapportage 2016 [cited 2018 Dec 3]. Available from: https://dica.nl/media/993/DICA-2016-jaarverslag.pdf.
   Google Scholar